Validation of a quantitative susceptibility mapping acquisition and reconstruction pipeline using a new iron sucrose based MR susceptibility phantom

Automated Quantitative Susceptibility and Morphometry MR Study: Feasibility and Interrelation Between Clinical Score, Lesion Load, Deep Grey Matter and Normal-Appearing White Matter in Multiple Sclerosis

INTRODUCTION

Lesion load (LL), deep gray matter (DGM) and normal-appearing white matter (NAWM) susceptibility and morphometry may help in monitoring brain changes in multiple sclerosis (MS) patients. We aimed at evaluating the feasibility of a fully automated segmentation and the potential interrelation between these biomarkers and clinical disability.

METHODS

Sixty-six patients with brain MRIs and clinical evaluations (Expanded Disability Status Scale [EDSS]) were retrospectively included. Automated prototypes were used for the segmentation and morphometry of brain regions (MorphoBox) and MS lesions (LeManPV). Susceptibility maps were estimated using standard post-processing (RESHARP and TVSB). Spearman's rho was computed to evaluate the interrelation between biomarkers and EDSS.

RESULTS

We found (i) anticorrelations between the LL and right thalamus susceptibility (rho = -0.46, p < 0.001) and between the LL and NAWM susceptibility (rho = [-0.68 to -0.25], p ≤ 0.05); (ii) an anticorrelation between LL and DGM (rho = [-0.71 to -0.36], p < 0.04) and WM morphometry (rho = [-0.64 to -0.28], p ≤ 0.01); and (iii) a positive correlation between EDSS and LL (rho = [0.28 to 0.5], p ≤ 0.03) and anticorrelation between EDSS and NAWM susceptibility (rho = [-0.29 to -0.38], p < 0.014).

CONCLUSIONS

Fully automated brain morphometry and susceptibility monitoring is feasible in MS patients. The lesion load, thalamus and NAWM susceptibility values and trophicity are interrelated and correlate with disability.

Motion artifacts in standard clinical setting obscure disease-specific differences in quantitative susceptibility mapping

As quantitative susceptibility mapping (QSM) is maturing, more clinical applications are being explored. With this comes the question whether QSM is sufficiently robust and reproducible to be directly used in a clinical setting where patients are possibly not cooperative and/or unable to suppress involuntary movements sufficiently. Twenty-nine patients with Alzheimer's disease, 31 patients with mild cognitive impairment and 41 healthy controls were scanned on a 3 T scanner, including a multi-echo gradient-echo sequence for QSM and an inversion-prepared segmented gradient-echo sequence (T1-TFE, MPRAGE). The severity of motion artifacts (excessive/strong/noticeable/invisible) was categorized via visual inspection by two independent raters. Quantitative susceptibility was reconstructed using 'joint background-field removal and segmentation-enhanced dipole inversion', based on segmented subcortical gray-matter regions, as well as using 'morphology enabled dipole inversion'. Statistical analysis of the susceptibility maps was performed per region. A large fraction of the data showed motion artifacts, visible in both magnitude images and susceptibility maps. No statistically significant susceptibility differences were found between groups including motion-affected data. Considering only subjects without visible motion, significant susceptibility differences were observed in caudate nucleus as well as in putamen. Motion-effects can obscure statistically significant differences in QSM between patients and controls. Additional measures to restrict and/or compensate for subject motion should be taken for QSM in standard clinical settings to avoid risk of false findings.